News

Mesenchymal Stem Cells Show Potential to Treat NTM Lung Infections

Treatment with human mesenchymal stem cells (MSCs) effectively lessened hard-to-treat non-tuberculous mycobacteria (NTM) lung infection, and its associated weight loss, in a new mouse model susceptible to these infections, an early study reported. “The potential to use human mesenchymal stem cells to treat difficult lung infections is promising,” Anthony Atala,…

Cough Monitoring App for COPD Added to NuvoAir Home Platform

NuvoAir has released a new mobile app for home use, called NuvoAir Cough, that can record and analyze coughing sounds made by patients with lung conditions, such as chronic obstructive pulmonary disease (COPD). The app is included in the NuvoAir Home platform, the company’s digital respiratory support system. Coughing…

Nebulized Ensifentrine Shows Promise as Add-on Therapy

Verona Pharma has announced positive efficacy and safety results about using nebulized ensifentrine as an add-on therapy to tiotropium (Spiriva Respimat) for treating symptomatic chronic obstructive pulmonary disease (COPD). Results from the Phase 2b clinical trial (NCT03937479) show that ensifentrine treatment, combined with maintenance tiotropium, results in…

Certain Mitochondrial Protein May Help Protect Airways in COPD

Scientists have found that a certain protein helps cells in the airways to clear away mucus, such as the mucus that builds up in chronic obstructive pulmonary disease (COPD). This discovery, they noted, suggests that boosting the activity of this protein, called adenine nucleotide translocase (ANT), could become a…

Study Identifies Patient Risk Factors for In-hospital Death

Certain risk factors may accurately predict in-hospital mortality, or death, in people with acute exacerbations of chronic obstructive pulmonary disease (COPD), a study revealed. These factors include the need for invasive mechanical ventilation (IMV), having chronic heart failure, and having a low number of immune white blood cells,…

Respinova Wins FDA OK for Airway Opening System Pulsehaler

Respinova’s new airway device, called Pulsehaler, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). That means it can be marketed as a safe and effective medical device to ease breathing in people with airway restrictions, such as chronic obstructive pulmonary disease (COPD). “We…